NCT03621085View on ClinicalTrials.gov

Analgesics in the Pre-hospital Setting: Implications on Hemorrhage Tolerance - Ketamine

PHASE4CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

June 1, 2018

Primary Completion Date

June 30, 2021

Study Completion Date

June 30, 2021

Conditions
HemorrhageHealthy
Interventions
DRUG

Ketamine Hydrochloride

A total of 20 mg of Ketamine Hydrochloride will be administered intravenously

OTHER

Placebo

Subjects will receive placebo

Trial Locations (1)

75231

Texas Health Presbyterian Hospital Dallas, Dallas

All Listed Sponsors
collaborator

United States Department of Defense

FED

lead

University of Texas Southwestern Medical Center

OTHER

NCT03621085 - Analgesics in the Pre-hospital Setting: Implications on Hemorrhage Tolerance - Ketamine | Biotech Hunter | Biotech Hunter